Latest Headlines

  1. Orchard Therapeutics To Invest $150M Into New Gene Therapy Manufacturing Facility In California
    12/13/2018

    Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that it has signed a long-term lease agreement to build-out a gene therapy manufacturing facility in Fremont, California.

  2. Cell Processing, Gene Therapy And Pharma 4.0 To Be Featured At Interphex 2019
    11/28/2018

    International Pharmaceutical Expo (INTERPHEX), the premier event dedicated to pharmaceutical and biotechnology innovation, technology and knowledge from development through commercialization, announces INNOPHEX will debut at INTERPHEX 2019.

  3. Cobra Biologics, Pall Corporation And The Cell And Gene Therapy Catapult Win £1.5M Innovate UK Grant To Investigate Continuous Manufacturing For Gene Therapies
    11/27/2018

    Cobra Biologics, an international contract development and manufacturing organization (CDMO) with a focus on advanced therapy medicinal products (ATMPs) has won a £1.5m shared grant from Innovate UK, the United Kingdom’s innovation agency.

  4. Reducing The Risk Of Bio-contamination In Gene, Cell And CAR-T Therapy
    11/7/2018

    Bioquell’s Dr Rolf Hansen examines how the latest isolator systems create aseptic working conditions for reducing risk and keeping gene, cell and CAR-T therapies efficient, compliant and accurate, whilst also supporting biologics manufacturing expansion and enabling more patients to be treated at the same time.

  5. How To Implement Cleanroom Upgrades While Operating Your Facility
    10/29/2018

    It goes without saying that upgrades during a manufacturing shutdown pose less risk as there are no products being produced, but there are instances when it is critical to expand capacity or modify functionality while maintaining some processing.

  6. Lonza Opens Cell And-Gene-Therapy Center Of Excellence In Texas
    10/15/2018

    Lonza reported it opened “the world’s largest dedicated cell and-gene-therapy Center of Excellence,” in Pearland, Texas. The COE is expected to reach 200 full-time staff by end of 2018 in greater Houston and continue to recruit high-value positions as market demand increases.

  7. Extract Technology To Exhibit Cell Therapy Isolator At PDA Cell And Gene Therapy Conference
    10/11/2018

    The 2018 PDA Cell and Gene Therapy Conference (October 23-24) will provide a broad overview of current innovations with a focus on what it takes to successfully steward these therapies toward approval and beyond.

  8. MilliporeSigma Offers Rhabdovirus-Free Insect Platform For Viral Vaccines And Gene Therapy Development
    10/10/2018

    MilliporeSigma is collaborating with GlycoBac LLC to offer a Sf-9 insect cell line. GlycoBac’s development of a proven rhabdovirus-negative (RVN) cell line enables MilliporeSigma to offer the first Sf-9 platform combining a rhabdovirus-free insect cell line with a corresponding, chemically defined cell culture medium. This will be the first non-mammalian cell line in MilliporeSigma’s cell culture portfolio, allowing customers worldwide access to a safer, high-performing vehicle for recombinant protein expression, Virus-like Particle vaccines and Adeno Associated Virus based gene therapy production.

  9. Rubius Therapeutics To Invest $155M Into New Cell Therapy Drug Manufacturing Facility In RI
    10/4/2018

    Rubius Therapeutics is investing $155M on a newly designed pharmaceutical manufacturing facility in Smithfield, Rhode Island.

  10. Novo Nordisk To Establish Manufacturing Site In California For Stem Cell-Based Drug Therapies
    10/1/2018

    Novo Nordisk recently announced the establishment of a manufacturing site in Fremont, California, US to develop and produce stem cell-based therapies. The announcement follows the signing of a long-term lease on a good manufacturing practice (GMP) facility, previously operated by Asterias Biotherapeutics.